<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556762</url>
  </required_header>
  <id_info>
    <org_study_id>SUMC-EC-002</org_study_id>
    <nct_id>NCT02556762</nct_id>
  </id_info>
  <brief_title>Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer</brief_title>
  <acronym>SUMC-EC-002</acronym>
  <official_title>Phase III Randomized Controlled Trial of Definite Chemoradiotherapy in Patients With Esophageal Cancer: Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuangzhen Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shantou University Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial is to compare simultaneous modulated accelerated boost with
      standard dose radiotherapy given together with chemotherapy in treating patients with
      esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-regional control</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities using CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>The probabilities of grade ≥ 3 acute toxicities and 2-year late toxicities of esophagus and lungs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed with FACT-E</measure>
    <time_frame>2 years</time_frame>
    <description>FACT-E score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured with EQ-5D</measure>
    <time_frame>2 years</time_frame>
    <description>The score of EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>SMART boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with simultaneous modulated accelerated boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with simultaneous modulated accelerated boost</intervention_name>
    <description>Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases</description>
    <arm_group_label>SMART boost</arm_group_label>
    <other_name>SIB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard dose radiotherapy</intervention_name>
    <description>Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease</description>
    <arm_group_label>Standard dose RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF</intervention_name>
    <description>Chemotherapy: Cisplatin and 5fluorouracil</description>
    <arm_group_label>SMART boost</arm_group_label>
    <arm_group_label>Standard dose RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic proof of primary squamous cell carcinoma of the esophagus.

          -  Primary disease at cervical, upper or middle thoracic esophagus

          -  T1-4, N any, M0 (except supraclavicular lymph node).

          -  Age≥18 &amp; ≤75.

          -  ECOG score 0-2.

          -  Platelets ≥ 150,000, Hgb ≥ 10 gm%, ANC ≥ 1500, serum creatinine ≤ 1.5 mg/dl.

          -  Adequate liver function.

          -  Patients with prior malignancy are eligible if disease-free ≥ 5 years.

          -  No prior chest radiotherapy, systemic chemotherapy or major esophageal surgery.

          -  Signed study-specific informed consent form prior to study entry.

        Exclusion Criteria:

          -  Patients with tracheo-esophageal fistula.

          -  Patients with invasion into mucosa of trachea or major bronchi.

          -  Patients with uncontrolled serious medical or mental illnesses.

          -  Prior RT that would result in overlap of planned RT fields.

          -  Pregnancy or women of childbearing potential and men who are sexually active

          -  Women who are breastfeeding a baby.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuangzhen Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Shantou University Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruihong Huang</last_name>
    <email>15989849684@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianzhou Chen, MD</last_name>
    <phone>86-13417049908</phone>
    <email>cjzeoeo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital, Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuangzhen Chen, MD</last_name>
      <phone>86-13923995569</phone>
      <email>stccz@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianzhou Chen, MD</last_name>
      <phone>86-13417049908</phone>
      <email>cjzeoeo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chuangzhen Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shantou University Medical College</investigator_affiliation>
    <investigator_full_name>Chuangzhen Chen</investigator_full_name>
    <investigator_title>M.D</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Simultaneous modulated accelerated boost</keyword>
  <keyword>Standard dose radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

